chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 73.0
Sex: M
Vaccine: COVID19, COVID19, COVID19, COVID19
Symptoms: Neurological symptom, Plasmapheresis, Platelet count decreased, Thrombotic thrombocytopenic purpura, Transient ischaemic attack
Clinical narrative: Patient received Moderna COVID vaccine on 2/21/2021.  He presented to an Emergency Department 3/19/2021 with altered speech, numbness on the left side of the face, and thrombocytopenia.  He was admitted to the Hospital with a diagnosis of TIA.   He continued to have thrombocytopenia, and lab testing suggests TTP.  Patient did receive 2nd dose of Moderna vaccine 3/21/2021 (lot # 007B21A) in the L arm.
Age: 73.0
Sex: M
Vaccine: COVID19, COVID19, COVID19, COVID19
Symptoms: ADAMTS13 activity abnormal, Arteriosclerosis, Cerebral ischaemia, Computerised tomogram head abnormal, Hypoaesthesia
Clinical narrative: Patient received Moderna COVID vaccine on 2/21/2021.  He presented to an Emergency Department 3/19/2021 with altered speech, numbness on the left side of the face, and thrombocytopenia.  He was admitted to the Hospital with a diagnosis of TIA.   He continued to have thrombocytopenia, and lab testing suggests TTP.  Patient did receive 2nd dose of Moderna vaccine 3/21/2021 (lot # 007B21A) in the L arm.
Age: 73.0
Sex: M
Vaccine: COVID19, COVID19, COVID19, COVID19
Symptoms: Magnetic resonance imaging head abnormal, Platelet count decreased, Speech disorder, Thrombocytopenia, Thrombotic thrombocytopenic purpura
Clinical narrative: Patient received Moderna COVID vaccine on 2/21/2021.  He presented to an Emergency Department 3/19/2021 with altered speech, numbness on the left side of the face, and thrombocytopenia.  He was admitted to the Hospital with a diagnosis of TIA.   He continued to have thrombocytopenia, and lab testing suggests TTP.  Patient did receive 2nd dose of Moderna vaccine 3/21/2021 (lot # 007B21A) in the L arm.
Age: 73.0
Sex: M
Vaccine: COVID19, COVID19, COVID19, COVID19
Symptoms: Transient ischaemic attack
Clinical narrative: Patient received Moderna COVID vaccine on 2/21/2021.  He presented to an Emergency Department 3/19/2021 with altered speech, numbness on the left side of the face, and thrombocytopenia.  He was admitted to the Hospital with a diagnosis of TIA.   He continued to have thrombocytopenia, and lab testing suggests TTP.  Patient did receive 2nd dose of Moderna vaccine 3/21/2021 (lot # 007B21A) in the L arm.
Age: 60.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Blood pressure measurement, Dysphagia, Oral pruritus, Paraesthesia oral, Pharyngeal paraesthesia
Clinical narrative: palpitations, feeling of throat swelling, hives
Age: 60.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Throat irritation
Clinical narrative: palpitations, feeling of throat swelling, hives
Age: 60.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Anaphylactic reaction, Dyspnoea, Urticaria
Clinical narrative: palpitations, feeling of throat swelling, hives
Age: 60.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Palpitations, Pharyngeal swelling, Urticaria
Clinical narrative: palpitations, feeling of throat swelling, hives
Age: 51.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Cough, Dysphagia, Pharyngeal swelling, Throat irritation
Clinical narrative: Left side of throat and face swelling, shortness of breath--- >Diphenhydramine, famotidine, methylprednisolone, EpiPen at home--- > discharged to home from ER.
Age: 51.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Dyspnoea, Pharyngeal swelling, Swelling face
Clinical narrative: Left side of throat and face swelling, shortness of breath--- >Diphenhydramine, famotidine, methylprednisolone, EpiPen at home--- > discharged to home from ER.
Age: 68.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Erythema, Feeling abnormal, Peripheral swelling
Clinical narrative: cellulitis; swelling on left arm/vaccine location= Left arm; Aches and pains; This is a spontaneous report from a contactable consumer (patient). A 68-year-old female patient received second dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE; lot number and expiry date: unknown), via an unspecified route of administration, administered in Arm Left on 18Mar2021 14:00 (at 68-years-old) as single dose for COVID-19 immunization. Medical history included CLL, known allergies: penicillin. Patient is not pregnant. The patient's concomitant medications were not reported. The patient previously took first dose of bnt162b2, on 25Feb2021 11:00 AM (at 68-years-old), administered in Right arm for COVID-19 immunization. Facility type vaccine was in Pharmacy or Drug Store. The patient did not have other vaccine in four weeks, the patient had other medications in two weeks. Patient had no covid prior vaccination, and had not been tested for covid post vaccination. The patient experienced swelling on left arm followed by cellulitis within three days, went on cephalexin 500 mg three times a day for seven days. Aches and pains continuing since then. Aches where she have never ached before. And she was in great shape so this is an unwelcome surprise. Events started on 21Mar2021 15:45 with outcome of recovered with sequelae.   Information on lot/batch number has been requested.
Age: 68.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Cellulitis, Illness, Rash
Clinical narrative: cellulitis; swelling on left arm/vaccine location= Left arm; Aches and pains; This is a spontaneous report from a contactable consumer (patient). A 68-year-old female patient received second dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE; lot number and expiry date: unknown), via an unspecified route of administration, administered in Arm Left on 18Mar2021 14:00 (at 68-years-old) as single dose for COVID-19 immunization. Medical history included CLL, known allergies: penicillin. Patient is not pregnant. The patient's concomitant medications were not reported. The patient previously took first dose of bnt162b2, on 25Feb2021 11:00 AM (at 68-years-old), administered in Right arm for COVID-19 immunization. Facility type vaccine was in Pharmacy or Drug Store. The patient did not have other vaccine in four weeks, the patient had other medications in two weeks. Patient had no covid prior vaccination, and had not been tested for covid post vaccination. The patient experienced swelling on left arm followed by cellulitis within three days, went on cephalexin 500 mg three times a day for seven days. Aches and pains continuing since then. Aches where she have never ached before. And she was in great shape so this is an unwelcome surprise. Events started on 21Mar2021 15:45 with outcome of recovered with sequelae.   Information on lot/batch number has been requested.
Age: 68.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Cellulitis, Pain, Vaccination site swelling
Clinical narrative: cellulitis; swelling on left arm/vaccine location= Left arm; Aches and pains; This is a spontaneous report from a contactable consumer (patient). A 68-year-old female patient received second dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE; lot number and expiry date: unknown), via an unspecified route of administration, administered in Arm Left on 18Mar2021 14:00 (at 68-years-old) as single dose for COVID-19 immunization. Medical history included CLL, known allergies: penicillin. Patient is not pregnant. The patient's concomitant medications were not reported. The patient previously took first dose of bnt162b2, on 25Feb2021 11:00 AM (at 68-years-old), administered in Right arm for COVID-19 immunization. Facility type vaccine was in Pharmacy or Drug Store. The patient did not have other vaccine in four weeks, the patient had other medications in two weeks. Patient had no covid prior vaccination, and had not been tested for covid post vaccination. The patient experienced swelling on left arm followed by cellulitis within three days, went on cephalexin 500 mg three times a day for seven days. Aches and pains continuing since then. Aches where she have never ached before. And she was in great shape so this is an unwelcome surprise. Events started on 21Mar2021 15:45 with outcome of recovered with sequelae.   Information on lot/batch number has been requested.
Age: 33.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Chest discomfort, Dizziness
Clinical narrative: Patient was vaccinated with Pfizer Vaccine on 3/31/2021. Patient denies having any immediate symptoms of allergic reaction. Patient was taking phentermine diet pills for 10 days prior to receiving her first dose of the Pfizer vaccine and continued with use for 10 days following her Pfizer vaccine dose. Patient states she experienced her "throat closing up" 9 days following her first dose of the Pfizer vaccine (April 9, 2021). Patient states the swelling was severe and affected her ability to swallow. Patient did not consult with doctor following symptoms. Patient states she took Amoxicillin for 2 days following adverse event because she "thought it was an infection". Amoxicillin was not prescribed to patient. Patient states her symptoms relieved following use of amoxicillin (4/11/2021).
Age: 33.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Dysphagia, Pharyngeal swelling
Clinical narrative: Patient was vaccinated with Pfizer Vaccine on 3/31/2021. Patient denies having any immediate symptoms of allergic reaction. Patient was taking phentermine diet pills for 10 days prior to receiving her first dose of the Pfizer vaccine and continued with use for 10 days following her Pfizer vaccine dose. Patient states she experienced her "throat closing up" 9 days following her first dose of the Pfizer vaccine (April 9, 2021). Patient states the swelling was severe and affected her ability to swallow. Patient did not consult with doctor following symptoms. Patient states she took Amoxicillin for 2 days following adverse event because she "thought it was an infection". Amoxicillin was not prescribed to patient. Patient states her symptoms relieved following use of amoxicillin (4/11/2021).
Age: 84.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Haemorrhagic stroke, Headache, Speech disorder
Clinical narrative: stroke/ brain hemorrhage; Trouble speaking; Terrible headache; This spontaneous case was reported by a consumer (subsequently medically confirmed) and describes the occurrence of HAEMORRHAGIC STROKE (stroke/ brain hemorrhage) in an 84-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 026L20A) for COVID-19 immunisation. The occurrence of additional non-serious events is detailed below.     The patient's past medical history included Stroke in 2017, Asthma since an unknown date, Psoriasis (Stelara injections since 2020) since an unknown date, Essential tremor and Stress test on 10-Feb-2021. Concomitant products included FLUTICASONE FUROATE, VILANTEROL TRIFENATATE (BREO ELLIPTA) for Asthma, PRAVASTATIN SODIUM (PRAVASTINE) for Cholesterol, PRIMIDONE for Essential tremor, AMLODIPINE BESILATE (AMLODIPINE (ALS BESILAAT) SANDOZ) and LISINOPRIL for an unknown indication.    On 14-Jan-2021 at 3:30 PM, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 14-Jan-2021, the patient experienced HEADACHE (Terrible headache). On 15-Jan-2021, the patient experienced APHASIA (Trouble speaking). On 15-Jan-2021 at 10:00 AM, the patient experienced HAEMORRHAGIC STROKE (stroke/ brain hemorrhage) (seriousness criteria hospitalization and medically significant). The patient was hospitalized from 15-Jan-2021 to 20-Jan-2021 due to HAEMORRHAGIC STROKE. At the time of the report, HAEMORRHAGIC STROKE (stroke/ brain hemorrhage) had not resolved, APHASIA (Trouble speaking) was resolving and HEADACHE (Terrible headache) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Based on the current available information and the temporal association between the product use and the start date of the events a causal relationship cannot be excluded.   Most recent FOLLOW-UP information incorporated above includes: On 07-Apr-2021: Follow-up included vaccine Lot/Batch number, patient details, past medical history, concomitant products, reported events start date and outcome.; Reporter's Comments: patient's advanced age and prior history of stroke may have been contributory.; Sender's Comments: Based on the current available information and the temporal association between the product use and the start date of the events a causal relationship cannot be excluded.
Age: 84.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Aphasia, Haemorrhagic stroke, Headache
Clinical narrative: stroke/ brain hemorrhage; Trouble speaking; Terrible headache; This spontaneous case was reported by a consumer (subsequently medically confirmed) and describes the occurrence of HAEMORRHAGIC STROKE (stroke/ brain hemorrhage) in an 84-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 026L20A) for COVID-19 immunisation. The occurrence of additional non-serious events is detailed below.     The patient's past medical history included Stroke in 2017, Asthma since an unknown date, Psoriasis (Stelara injections since 2020) since an unknown date, Essential tremor and Stress test on 10-Feb-2021. Concomitant products included FLUTICASONE FUROATE, VILANTEROL TRIFENATATE (BREO ELLIPTA) for Asthma, PRAVASTATIN SODIUM (PRAVASTINE) for Cholesterol, PRIMIDONE for Essential tremor, AMLODIPINE BESILATE (AMLODIPINE (ALS BESILAAT) SANDOZ) and LISINOPRIL for an unknown indication.    On 14-Jan-2021 at 3:30 PM, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 14-Jan-2021, the patient experienced HEADACHE (Terrible headache). On 15-Jan-2021, the patient experienced APHASIA (Trouble speaking). On 15-Jan-2021 at 10:00 AM, the patient experienced HAEMORRHAGIC STROKE (stroke/ brain hemorrhage) (seriousness criteria hospitalization and medically significant). The patient was hospitalized from 15-Jan-2021 to 20-Jan-2021 due to HAEMORRHAGIC STROKE. At the time of the report, HAEMORRHAGIC STROKE (stroke/ brain hemorrhage) had not resolved, APHASIA (Trouble speaking) was resolving and HEADACHE (Terrible headache) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Based on the current available information and the temporal association between the product use and the start date of the events a causal relationship cannot be excluded.   Most recent FOLLOW-UP information incorporated above includes: On 07-Apr-2021: Follow-up included vaccine Lot/Batch number, patient details, past medical history, concomitant products, reported events start date and outcome.; Reporter's Comments: patient's advanced age and prior history of stroke may have been contributory.; Sender's Comments: Based on the current available information and the temporal association between the product use and the start date of the events a causal relationship cannot be excluded.
Age: 40.0
Sex: F
Vaccine: UNK, COVID19
Symptoms: Blood test normal, Hypoaesthesia, Magnetic resonance imaging head normal, Magnetic resonance imaging neck, Magnetic resonance imaging spinal normal
Clinical narrative: Numbness in right leg from the hip all the way down. A few days later, left leg went numb from the knee down. A week later, right arm went numb; This is a spontaneous report from a contactable consumer (patient herself). A 40-year-old female patient received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE; Solution for injection; Lot number: EW6206), via an unspecified route of administration on 16Mar2021 10:00 AM at single dose in left arm for COVID-19 immunization at hospital. The patient medical history included asthma, syncope and had allergy to sulfa. Patient was not pregnant at time of vaccination. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. Concomitant medications included loratadine (CLARITINE), and Multivitamin within 2 weeks of vaccination. On 16Mar2021 18:00, the patient experienced numbness in right leg from the hip all the way down, a few days later, left leg went numb from the knee down. a week later, right arm went numb, and patient was hospitalized for 1 day. The patient did not receive any treatment for the event. The event resulted in Emergency room/department or urgent care. The outcome of the event was not recovered.  Information on Lot/Batch number was available. Additional information has been requested
Age: 40.0
Sex: F
Vaccine: UNK, COVID19
Symptoms: Hypoaesthesia
Clinical narrative: Numbness in right leg from the hip all the way down. A few days later, left leg went numb from the knee down. A week later, right arm went numb; This is a spontaneous report from a contactable consumer (patient herself). A 40-year-old female patient received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE; Solution for injection; Lot number: EW6206), via an unspecified route of administration on 16Mar2021 10:00 AM at single dose in left arm for COVID-19 immunization at hospital. The patient medical history included asthma, syncope and had allergy to sulfa. Patient was not pregnant at time of vaccination. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. Concomitant medications included loratadine (CLARITINE), and Multivitamin within 2 weeks of vaccination. On 16Mar2021 18:00, the patient experienced numbness in right leg from the hip all the way down, a few days later, left leg went numb from the knee down. a week later, right arm went numb, and patient was hospitalized for 1 day. The patient did not receive any treatment for the event. The event resulted in Emergency room/department or urgent care. The outcome of the event was not recovered.  Information on Lot/Batch number was available. Additional information has been requested
Age: 32.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Erythema, Feeling hot, Flushing, Hyperhidrosis, Pruritus
Clinical narrative: Fainting; Swelling of arms and hands; Feeling hot; Hives on the face and limbs; Shortness of breath; This is a spontaneous report from a contactable consumer (patient). A 32-year-old male patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection) (at 32 years of age), dose 1 via an unspecified route of administration, administered in arm left on 31Mar2021 14:30 (Batch/Lot Number: EW0150) as a single dose for COVID-19 immunisation. Medical history was None. The patient's concomitant medications were not reported. The patient did not receive any other vaccine within 4 weeks prior to the covid vaccine. He was not diagnosed with Covid-19 prior to vaccination. He has not been tested for covid since the vaccination. He had no allergies to medications, food, or other products. The patient experienced swelling of arms and hands, feeling hot, hives on the face and limbs. He also had shortness of breath and fainting. The events started on 31Mar2021 18:45 with outcome of recovered with sequelae. Therapeutic measures were taken as a result of the events as the patient was administered with IV saline, steroids and antihistamine. The events resulted to Emergency room/department or urgent care.  Information on the lot/batch number has been requested.
Age: 32.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Syncope
Clinical narrative: Fainting; Swelling of arms and hands; Feeling hot; Hives on the face and limbs; Shortness of breath; This is a spontaneous report from a contactable consumer (patient). A 32-year-old male patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection) (at 32 years of age), dose 1 via an unspecified route of administration, administered in arm left on 31Mar2021 14:30 (Batch/Lot Number: EW0150) as a single dose for COVID-19 immunisation. Medical history was None. The patient's concomitant medications were not reported. The patient did not receive any other vaccine within 4 weeks prior to the covid vaccine. He was not diagnosed with Covid-19 prior to vaccination. He has not been tested for covid since the vaccination. He had no allergies to medications, food, or other products. The patient experienced swelling of arms and hands, feeling hot, hives on the face and limbs. He also had shortness of breath and fainting. The events started on 31Mar2021 18:45 with outcome of recovered with sequelae. Therapeutic measures were taken as a result of the events as the patient was administered with IV saline, steroids and antihistamine. The events resulted to Emergency room/department or urgent care.  Information on the lot/batch number has been requested.
Age: 32.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Dyspnoea, Feeling hot, Peripheral swelling, Syncope, Urticaria
Clinical narrative: Fainting; Swelling of arms and hands; Feeling hot; Hives on the face and limbs; Shortness of breath; This is a spontaneous report from a contactable consumer (patient). A 32-year-old male patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection) (at 32 years of age), dose 1 via an unspecified route of administration, administered in arm left on 31Mar2021 14:30 (Batch/Lot Number: EW0150) as a single dose for COVID-19 immunisation. Medical history was None. The patient's concomitant medications were not reported. The patient did not receive any other vaccine within 4 weeks prior to the covid vaccine. He was not diagnosed with Covid-19 prior to vaccination. He has not been tested for covid since the vaccination. He had no allergies to medications, food, or other products. The patient experienced swelling of arms and hands, feeling hot, hives on the face and limbs. He also had shortness of breath and fainting. The events started on 31Mar2021 18:45 with outcome of recovered with sequelae. Therapeutic measures were taken as a result of the events as the patient was administered with IV saline, steroids and antihistamine. The events resulted to Emergency room/department or urgent care.  Information on the lot/batch number has been requested.
Age: 80.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Chest pain, Computerised tomogram normal, Defaecation disorder, Muscle spasms, Urine analysis abnormal
Clinical narrative: worsening abdominal pain x 2 weeks which has subsided went to ER  on 3/23/21 and received pain patch, tylenol and intravenous muscle relaxer, CAT scan was done on lumbar and abdomen, results were negative. No longer has signs and symptoms at this time.
Age: 80.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Abdominal pain, Computerised tomogram normal
Clinical narrative: worsening abdominal pain x 2 weeks which has subsided went to ER  on 3/23/21 and received pain patch, tylenol and intravenous muscle relaxer, CAT scan was done on lumbar and abdomen, results were negative. No longer has signs and symptoms at this time.
Age: 64.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Computerised tomogram head, Deafness
Clinical narrative: Hearing loss on left ear; This is a spontaneous report from a contactable consumer (patient).   A 64-years-old female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE), dose 2 via an unspecified route of administration, administered in Arm Left on 22Mar2021 13:30 (Lot Number: ER8782), age at vaccination of 64-years-old as single dose for covid-19 immunisation. Medical history included thyroid disorder from an unknown date and unknown if ongoing, hypertension from an unknown date and unknown if ongoing (high blood pressure). Patent was not pregnant and was not pregnant at the time of vaccination. The patient previously took naproxen and experienced drug hypersensitivity; patient received fist dose of bnt162b2 for covid-19 immunisation on an unspecified date (Lot Number not available).  The patient experienced hearing loss on left ear on 26Mar2021 14:30, that resulted in emergency room/department or urgent care. Therapeutic measures were taken as results of the event and included administration of steroid injection, prednisone and Meclizine. The patient did not receive other vaccine in four weeks; covid prior vaccination: No; Covid tested post vaccination: No. Outcome of the event was not recovered.
Age: 64.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Deafness
Clinical narrative: Hearing loss on left ear; This is a spontaneous report from a contactable consumer (patient).   A 64-years-old female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE), dose 2 via an unspecified route of administration, administered in Arm Left on 22Mar2021 13:30 (Lot Number: ER8782), age at vaccination of 64-years-old as single dose for covid-19 immunisation. Medical history included thyroid disorder from an unknown date and unknown if ongoing, hypertension from an unknown date and unknown if ongoing (high blood pressure). Patent was not pregnant and was not pregnant at the time of vaccination. The patient previously took naproxen and experienced drug hypersensitivity; patient received fist dose of bnt162b2 for covid-19 immunisation on an unspecified date (Lot Number not available).  The patient experienced hearing loss on left ear on 26Mar2021 14:30, that resulted in emergency room/department or urgent care. Therapeutic measures were taken as results of the event and included administration of steroid injection, prednisone and Meclizine. The patient did not receive other vaccine in four weeks; covid prior vaccination: No; Covid tested post vaccination: No. Outcome of the event was not recovered.
Age: 45.0
Sex: M
Vaccine: COVID19, COVID19, COVID19, COVID19
Symptoms: Abdominal pain, Blood test, Computerised tomogram abdomen abnormal, Computerised tomogram pelvis, Malaise
Clinical narrative: Main portal vein, right portal vein, and SMV thrombus; This is a spontaneous report from a contactable consumer (patient). The 45-years-old male patient received bnt162b2, dose 2 via an unspecified route of administration, administered in Arm Left on 26Mar2021 07:15 (Batch/Lot Number: EP6955) as SINGLE DOSE for covid-19 immunization. The patient medical history was not reported. No known allergies. There were no concomitant medications. The patient previously received first dose of bnt162b2 on 05Mar2021 07:00 AM (lot number=EN62020) in right arm at single dose for Covid-19 immunization. No other vaccine in four weeks and Other medications in two weeks. No Covid prior vaccination. The patient experienced main portal vein, right portal vein, and smv thrombus on 29Mar2021 04:00.  The patient was hospitalized for the event for 4 days. The AE resulted in Emergency room/department or urgent care, Hospitalization, Life threatening illness (immediate risk of death from the event). The patient underwent Covid tested post vaccination via Nasal Swab for SARS-CoV-2 on 03Apr2021 and was negative. The patient was treated with heparin, currently on Xarelto. The outcome of the event was recovered with sequelae  No follow-up attempts are possible. No further information is expected.
Age: 45.0
Sex: M
Vaccine: COVID19, COVID19, COVID19, COVID19
Symptoms: Mesenteric vein thrombosis, Nausea, Oedematous pancreatitis, Portal vein thrombosis
Clinical narrative: Main portal vein, right portal vein, and SMV thrombus; This is a spontaneous report from a contactable consumer (patient). The 45-years-old male patient received bnt162b2, dose 2 via an unspecified route of administration, administered in Arm Left on 26Mar2021 07:15 (Batch/Lot Number: EP6955) as SINGLE DOSE for covid-19 immunization. The patient medical history was not reported. No known allergies. There were no concomitant medications. The patient previously received first dose of bnt162b2 on 05Mar2021 07:00 AM (lot number=EN62020) in right arm at single dose for Covid-19 immunization. No other vaccine in four weeks and Other medications in two weeks. No Covid prior vaccination. The patient experienced main portal vein, right portal vein, and smv thrombus on 29Mar2021 04:00.  The patient was hospitalized for the event for 4 days. The AE resulted in Emergency room/department or urgent care, Hospitalization, Life threatening illness (immediate risk of death from the event). The patient underwent Covid tested post vaccination via Nasal Swab for SARS-CoV-2 on 03Apr2021 and was negative. The patient was treated with heparin, currently on Xarelto. The outcome of the event was recovered with sequelae  No follow-up attempts are possible. No further information is expected.
Age: 45.0
Sex: M
Vaccine: COVID19, COVID19, COVID19, COVID19
Symptoms: Abdominal pain, Abnormal faeces, Bundle branch block right, Computerised tomogram abdomen, Decreased appetite
Clinical narrative: Main portal vein, right portal vein, and SMV thrombus; This is a spontaneous report from a contactable consumer (patient). The 45-years-old male patient received bnt162b2, dose 2 via an unspecified route of administration, administered in Arm Left on 26Mar2021 07:15 (Batch/Lot Number: EP6955) as SINGLE DOSE for covid-19 immunization. The patient medical history was not reported. No known allergies. There were no concomitant medications. The patient previously received first dose of bnt162b2 on 05Mar2021 07:00 AM (lot number=EN62020) in right arm at single dose for Covid-19 immunization. No other vaccine in four weeks and Other medications in two weeks. No Covid prior vaccination. The patient experienced main portal vein, right portal vein, and smv thrombus on 29Mar2021 04:00.  The patient was hospitalized for the event for 4 days. The AE resulted in Emergency room/department or urgent care, Hospitalization, Life threatening illness (immediate risk of death from the event). The patient underwent Covid tested post vaccination via Nasal Swab for SARS-CoV-2 on 03Apr2021 and was negative. The patient was treated with heparin, currently on Xarelto. The outcome of the event was recovered with sequelae  No follow-up attempts are possible. No further information is expected.
Age: 45.0
Sex: M
Vaccine: COVID19, COVID19, COVID19, COVID19
Symptoms: Dyspnoea, Electrocardiogram normal, Fatigue, Lipase normal, Muscle strain
Clinical narrative: Main portal vein, right portal vein, and SMV thrombus; This is a spontaneous report from a contactable consumer (patient). The 45-years-old male patient received bnt162b2, dose 2 via an unspecified route of administration, administered in Arm Left on 26Mar2021 07:15 (Batch/Lot Number: EP6955) as SINGLE DOSE for covid-19 immunization. The patient medical history was not reported. No known allergies. There were no concomitant medications. The patient previously received first dose of bnt162b2 on 05Mar2021 07:00 AM (lot number=EN62020) in right arm at single dose for Covid-19 immunization. No other vaccine in four weeks and Other medications in two weeks. No Covid prior vaccination. The patient experienced main portal vein, right portal vein, and smv thrombus on 29Mar2021 04:00.  The patient was hospitalized for the event for 4 days. The AE resulted in Emergency room/department or urgent care, Hospitalization, Life threatening illness (immediate risk of death from the event). The patient underwent Covid tested post vaccination via Nasal Swab for SARS-CoV-2 on 03Apr2021 and was negative. The patient was treated with heparin, currently on Xarelto. The outcome of the event was recovered with sequelae  No follow-up attempts are possible. No further information is expected.
Age: 45.0
Sex: M
Vaccine: COVID19, COVID19, COVID19, COVID19
Symptoms: Nausea, Oedema, Scan with contrast abnormal, Thrombosis, Vomiting
Clinical narrative: Main portal vein, right portal vein, and SMV thrombus; This is a spontaneous report from a contactable consumer (patient). The 45-years-old male patient received bnt162b2, dose 2 via an unspecified route of administration, administered in Arm Left on 26Mar2021 07:15 (Batch/Lot Number: EP6955) as SINGLE DOSE for covid-19 immunization. The patient medical history was not reported. No known allergies. There were no concomitant medications. The patient previously received first dose of bnt162b2 on 05Mar2021 07:00 AM (lot number=EN62020) in right arm at single dose for Covid-19 immunization. No other vaccine in four weeks and Other medications in two weeks. No Covid prior vaccination. The patient experienced main portal vein, right portal vein, and smv thrombus on 29Mar2021 04:00.  The patient was hospitalized for the event for 4 days. The AE resulted in Emergency room/department or urgent care, Hospitalization, Life threatening illness (immediate risk of death from the event). The patient underwent Covid tested post vaccination via Nasal Swab for SARS-CoV-2 on 03Apr2021 and was negative. The patient was treated with heparin, currently on Xarelto. The outcome of the event was recovered with sequelae  No follow-up attempts are possible. No further information is expected.
Age: 45.0
Sex: M
Vaccine: COVID19, COVID19, COVID19, COVID19
Symptoms: White blood cell count increased
Clinical narrative: Main portal vein, right portal vein, and SMV thrombus; This is a spontaneous report from a contactable consumer (patient). The 45-years-old male patient received bnt162b2, dose 2 via an unspecified route of administration, administered in Arm Left on 26Mar2021 07:15 (Batch/Lot Number: EP6955) as SINGLE DOSE for covid-19 immunization. The patient medical history was not reported. No known allergies. There were no concomitant medications. The patient previously received first dose of bnt162b2 on 05Mar2021 07:00 AM (lot number=EN62020) in right arm at single dose for Covid-19 immunization. No other vaccine in four weeks and Other medications in two weeks. No Covid prior vaccination. The patient experienced main portal vein, right portal vein, and smv thrombus on 29Mar2021 04:00.  The patient was hospitalized for the event for 4 days. The AE resulted in Emergency room/department or urgent care, Hospitalization, Life threatening illness (immediate risk of death from the event). The patient underwent Covid tested post vaccination via Nasal Swab for SARS-CoV-2 on 03Apr2021 and was negative. The patient was treated with heparin, currently on Xarelto. The outcome of the event was recovered with sequelae  No follow-up attempts are possible. No further information is expected.
Age: 45.0
Sex: M
Vaccine: COVID19, COVID19, COVID19, COVID19
Symptoms: Abdominal pain lower, Abdominal pain upper, Activated partial thromboplastin time shortened, Anticoagulant therapy, Computerised tomogram abdomen
Clinical narrative: Main portal vein, right portal vein, and SMV thrombus; This is a spontaneous report from a contactable consumer (patient). The 45-years-old male patient received bnt162b2, dose 2 via an unspecified route of administration, administered in Arm Left on 26Mar2021 07:15 (Batch/Lot Number: EP6955) as SINGLE DOSE for covid-19 immunization. The patient medical history was not reported. No known allergies. There were no concomitant medications. The patient previously received first dose of bnt162b2 on 05Mar2021 07:00 AM (lot number=EN62020) in right arm at single dose for Covid-19 immunization. No other vaccine in four weeks and Other medications in two weeks. No Covid prior vaccination. The patient experienced main portal vein, right portal vein, and smv thrombus on 29Mar2021 04:00.  The patient was hospitalized for the event for 4 days. The AE resulted in Emergency room/department or urgent care, Hospitalization, Life threatening illness (immediate risk of death from the event). The patient underwent Covid tested post vaccination via Nasal Swab for SARS-CoV-2 on 03Apr2021 and was negative. The patient was treated with heparin, currently on Xarelto. The outcome of the event was recovered with sequelae  No follow-up attempts are possible. No further information is expected.
Age: 45.0
Sex: M
Vaccine: COVID19, COVID19, COVID19, COVID19
Symptoms: Computerised tomogram abnormal, Factor V Leiden mutation, Fatigue, Haematocrit normal, Haemoglobin normal
Clinical narrative: Main portal vein, right portal vein, and SMV thrombus; This is a spontaneous report from a contactable consumer (patient). The 45-years-old male patient received bnt162b2, dose 2 via an unspecified route of administration, administered in Arm Left on 26Mar2021 07:15 (Batch/Lot Number: EP6955) as SINGLE DOSE for covid-19 immunization. The patient medical history was not reported. No known allergies. There were no concomitant medications. The patient previously received first dose of bnt162b2 on 05Mar2021 07:00 AM (lot number=EN62020) in right arm at single dose for Covid-19 immunization. No other vaccine in four weeks and Other medications in two weeks. No Covid prior vaccination. The patient experienced main portal vein, right portal vein, and smv thrombus on 29Mar2021 04:00.  The patient was hospitalized for the event for 4 days. The AE resulted in Emergency room/department or urgent care, Hospitalization, Life threatening illness (immediate risk of death from the event). The patient underwent Covid tested post vaccination via Nasal Swab for SARS-CoV-2 on 03Apr2021 and was negative. The patient was treated with heparin, currently on Xarelto. The outcome of the event was recovered with sequelae  No follow-up attempts are possible. No further information is expected.
Age: 45.0
Sex: M
Vaccine: COVID19, COVID19, COVID19, COVID19
Symptoms: Headache, International normalised ratio increased, Mean cell haemoglobin concentration normal, Mean cell haemoglobin normal, Mean cell volume normal
Clinical narrative: Main portal vein, right portal vein, and SMV thrombus; This is a spontaneous report from a contactable consumer (patient). The 45-years-old male patient received bnt162b2, dose 2 via an unspecified route of administration, administered in Arm Left on 26Mar2021 07:15 (Batch/Lot Number: EP6955) as SINGLE DOSE for covid-19 immunization. The patient medical history was not reported. No known allergies. There were no concomitant medications. The patient previously received first dose of bnt162b2 on 05Mar2021 07:00 AM (lot number=EN62020) in right arm at single dose for Covid-19 immunization. No other vaccine in four weeks and Other medications in two weeks. No Covid prior vaccination. The patient experienced main portal vein, right portal vein, and smv thrombus on 29Mar2021 04:00.  The patient was hospitalized for the event for 4 days. The AE resulted in Emergency room/department or urgent care, Hospitalization, Life threatening illness (immediate risk of death from the event). The patient underwent Covid tested post vaccination via Nasal Swab for SARS-CoV-2 on 03Apr2021 and was negative. The patient was treated with heparin, currently on Xarelto. The outcome of the event was recovered with sequelae  No follow-up attempts are possible. No further information is expected.
Age: 45.0
Sex: M
Vaccine: COVID19, COVID19, COVID19, COVID19
Symptoms: Mean platelet volume normal, Platelet count normal, Protein C, Protein S, Red blood cell count normal
Clinical narrative: Main portal vein, right portal vein, and SMV thrombus; This is a spontaneous report from a contactable consumer (patient). The 45-years-old male patient received bnt162b2, dose 2 via an unspecified route of administration, administered in Arm Left on 26Mar2021 07:15 (Batch/Lot Number: EP6955) as SINGLE DOSE for covid-19 immunization. The patient medical history was not reported. No known allergies. There were no concomitant medications. The patient previously received first dose of bnt162b2 on 05Mar2021 07:00 AM (lot number=EN62020) in right arm at single dose for Covid-19 immunization. No other vaccine in four weeks and Other medications in two weeks. No Covid prior vaccination. The patient experienced main portal vein, right portal vein, and smv thrombus on 29Mar2021 04:00.  The patient was hospitalized for the event for 4 days. The AE resulted in Emergency room/department or urgent care, Hospitalization, Life threatening illness (immediate risk of death from the event). The patient underwent Covid tested post vaccination via Nasal Swab for SARS-CoV-2 on 03Apr2021 and was negative. The patient was treated with heparin, currently on Xarelto. The outcome of the event was recovered with sequelae  No follow-up attempts are possible. No further information is expected.
Age: 45.0
Sex: M
Vaccine: COVID19, COVID19, COVID19, COVID19
Symptoms: Red cell distribution width normal, Scan with contrast abnormal, Thrombosis mesenteric vessel, Vomiting, White blood cell count abnormal
Clinical narrative: Main portal vein, right portal vein, and SMV thrombus; This is a spontaneous report from a contactable consumer (patient). The 45-years-old male patient received bnt162b2, dose 2 via an unspecified route of administration, administered in Arm Left on 26Mar2021 07:15 (Batch/Lot Number: EP6955) as SINGLE DOSE for covid-19 immunization. The patient medical history was not reported. No known allergies. There were no concomitant medications. The patient previously received first dose of bnt162b2 on 05Mar2021 07:00 AM (lot number=EN62020) in right arm at single dose for Covid-19 immunization. No other vaccine in four weeks and Other medications in two weeks. No Covid prior vaccination. The patient experienced main portal vein, right portal vein, and smv thrombus on 29Mar2021 04:00.  The patient was hospitalized for the event for 4 days. The AE resulted in Emergency room/department or urgent care, Hospitalization, Life threatening illness (immediate risk of death from the event). The patient underwent Covid tested post vaccination via Nasal Swab for SARS-CoV-2 on 03Apr2021 and was negative. The patient was treated with heparin, currently on Xarelto. The outcome of the event was recovered with sequelae  No follow-up attempts are possible. No further information is expected.
Age: 45.0
Sex: M
Vaccine: COVID19, COVID19, COVID19, COVID19
Symptoms: Portal vein thrombosis, SARS-CoV-2 test
Clinical narrative: Main portal vein, right portal vein, and SMV thrombus; This is a spontaneous report from a contactable consumer (patient). The 45-years-old male patient received bnt162b2, dose 2 via an unspecified route of administration, administered in Arm Left on 26Mar2021 07:15 (Batch/Lot Number: EP6955) as SINGLE DOSE for covid-19 immunization. The patient medical history was not reported. No known allergies. There were no concomitant medications. The patient previously received first dose of bnt162b2 on 05Mar2021 07:00 AM (lot number=EN62020) in right arm at single dose for Covid-19 immunization. No other vaccine in four weeks and Other medications in two weeks. No Covid prior vaccination. The patient experienced main portal vein, right portal vein, and smv thrombus on 29Mar2021 04:00.  The patient was hospitalized for the event for 4 days. The AE resulted in Emergency room/department or urgent care, Hospitalization, Life threatening illness (immediate risk of death from the event). The patient underwent Covid tested post vaccination via Nasal Swab for SARS-CoV-2 on 03Apr2021 and was negative. The patient was treated with heparin, currently on Xarelto. The outcome of the event was recovered with sequelae  No follow-up attempts are possible. No further information is expected.
Age: 63.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Arthralgia, Arthritis, Dysgeusia, Dyspepsia, Ear discomfort
Clinical narrative: Peripheral neuropathy; Arthritis in neck hips and shoulders; Arthritis in neck hips and shoulders; Metallic taste on tongue; tingling on tongue; stomach muscle fatigue; itchy head; inability to clear ears; burning sensation in stomach; generalized sore muscles; generalized achy joints; enlarged or swollen lymph nodes; testicular pain; This is a spontaneous report from a contactable consumer (patient). A 63-year-old male patient received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, lot number: ER8730 and expiration date not provided) via an unspecified route of administration, administered in left arm on 22Mar2021 10:45 as a single dose for COVID-19 immunization. Medical history included pinched nerve in neck and allergies to Penicillin. The patient did not receive any other vaccine in 4 weeks prior to the COVID vaccine and no other medications in two weeks. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient's concomitant medications were not reported. On 22Mar2021 18:00, the patient experienced peripheral neuropathy, arthritis in neck hips and shoulders, metallic taste on tongue, tingling on tongue, stomach muscle fatigue, itchy head, inability to clear ears, burning sensation in stomach, generalized sore muscles, generalized achy joints, enlarged or swollen lymph nodes, and testicular pain. The events resulted in Doctor or other healthcare professional office/clinic visit and Disability or permanent damage. No treatment was given in response to the events. The outcome of the events was not recovered. The patient has not been tested for COVID-19 since having the vaccine.
Age: 63.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Head discomfort, Lymphadenopathy, Muscle fatigue, Myalgia, Neuropathy peripheral
Clinical narrative: Peripheral neuropathy; Arthritis in neck hips and shoulders; Arthritis in neck hips and shoulders; Metallic taste on tongue; tingling on tongue; stomach muscle fatigue; itchy head; inability to clear ears; burning sensation in stomach; generalized sore muscles; generalized achy joints; enlarged or swollen lymph nodes; testicular pain; This is a spontaneous report from a contactable consumer (patient). A 63-year-old male patient received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, lot number: ER8730 and expiration date not provided) via an unspecified route of administration, administered in left arm on 22Mar2021 10:45 as a single dose for COVID-19 immunization. Medical history included pinched nerve in neck and allergies to Penicillin. The patient did not receive any other vaccine in 4 weeks prior to the COVID vaccine and no other medications in two weeks. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient's concomitant medications were not reported. On 22Mar2021 18:00, the patient experienced peripheral neuropathy, arthritis in neck hips and shoulders, metallic taste on tongue, tingling on tongue, stomach muscle fatigue, itchy head, inability to clear ears, burning sensation in stomach, generalized sore muscles, generalized achy joints, enlarged or swollen lymph nodes, and testicular pain. The events resulted in Doctor or other healthcare professional office/clinic visit and Disability or permanent damage. No treatment was given in response to the events. The outcome of the events was not recovered. The patient has not been tested for COVID-19 since having the vaccine.
Age: 63.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Paraesthesia oral, Pruritus, Spondylitis, Testicular pain
Clinical narrative: Peripheral neuropathy; Arthritis in neck hips and shoulders; Arthritis in neck hips and shoulders; Metallic taste on tongue; tingling on tongue; stomach muscle fatigue; itchy head; inability to clear ears; burning sensation in stomach; generalized sore muscles; generalized achy joints; enlarged or swollen lymph nodes; testicular pain; This is a spontaneous report from a contactable consumer (patient). A 63-year-old male patient received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, lot number: ER8730 and expiration date not provided) via an unspecified route of administration, administered in left arm on 22Mar2021 10:45 as a single dose for COVID-19 immunization. Medical history included pinched nerve in neck and allergies to Penicillin. The patient did not receive any other vaccine in 4 weeks prior to the COVID vaccine and no other medications in two weeks. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient's concomitant medications were not reported. On 22Mar2021 18:00, the patient experienced peripheral neuropathy, arthritis in neck hips and shoulders, metallic taste on tongue, tingling on tongue, stomach muscle fatigue, itchy head, inability to clear ears, burning sensation in stomach, generalized sore muscles, generalized achy joints, enlarged or swollen lymph nodes, and testicular pain. The events resulted in Doctor or other healthcare professional office/clinic visit and Disability or permanent damage. No treatment was given in response to the events. The outcome of the events was not recovered. The patient has not been tested for COVID-19 since having the vaccine.